Menu
Back to Journals » Cancer Management and Research » Volume 5
Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
Authors Macha MA, Batra SK, Ganti AK
Received 30 March 2013
Accepted for publication 19 May 2013
Published 31 July 2013 Volume 2013:5 Pages 197—203
DOI https://doi.org/10.2147/CMAR.S45976
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Muzafar A Macha,1 Surinder K Batra,1,2 Apar Kishor Ganti3,4
1Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, 2Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, 3Department of Internal Medicine, VA Nebraska-Western Iowa Health Care System, Omaha, 4Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA
Abstract: Basal cell carcinoma (BCC) is the most common human malignancy. Recent advances in our understanding of the critical biologic pathways implicated in the development and progression of BCC have led to the development of the first molecular targeted therapy for this disease. The hedgehog pathway is mutated in virtually all patients with BCC and recent trials with vismodegib, an inhibitor of this pathway, have shown significant responses. This review will discuss the importance of the hedgehog pathway in the pathogenesis of BCC and describe in detail the pharmacology of vismodegib in relation to its activity in advanced BCC.
Keywords: basal cell carcinoma, vismodegib, hedgehog pathway
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.